Why Is MiNK Therapeutics Stock (INKT) Up Today?
TipRanks (Tue, 10-Mar 8:33 AM ET)
Market Chameleon (Tue, 10-Mar 3:05 AM ET)
MiNK Therapeutics rockets 60% after collaboration with C-Further for pediatric cancers
Seeking Alpha News (Tue, 10-Mar 6:49 AM ET)
Globe Newswire (Tue, 10-Mar 5:30 AM ET)
C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology
Business Wire (Tue, 10-Mar 5:00 AM ET)
Globe Newswire (Tue, 3-Feb 9:30 PM ET)
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Mink Therapeutics trades on the NASDAQ stock market under the symbol INKT.
As of March 10, 2026, INKT stock price climbed to $15.72 with 1,058,458 million shares trading.
INKT has a market cap of $73.79 million. This is considered a Micro Cap stock.
In the last 3 years, INKT traded as high as $76.00 and as low as $.46.
The top ETF exchange traded funds that INKT belongs to (by Net Assets): VTI, VXF.
INKT has outperformed the market in the last year with a price return of +91.7% while the SPY ETF gained +18.8%. INKT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +21.0% and +40.0%, respectively, while the SPY returned -0.6% and -0.8%, respectively.
INKT support price is $10.11 and resistance is $10.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that INKT shares will trade within this expected range on the day.
